FPR2 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-FPR2 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityFPR2
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formatimmunogen affinity purified
Size0.03 mL, 0.1 mL, 0.2 mL
Concentration1 mg/ml
ApplicationsWestern Blot (WB), ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThe antibody detects endogenous levels of FPR2 protein. FPR2 (Formyl Peptide Receptor 2) is a Protein Coding gene. Diseases associated with FPR2 include Prion Disease. Among its related pathways are Akt Signaling and Signaling by GPCR. GO annotations related to this gene include G-protein coupled receptor activity and N-formyl peptide receptor activity. An important paralog of this gene is FPR3. Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophils chemotactic factors. Binding of FMLP to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The activation of LXA4R could result in an anti-inflammatory outc
ImmunogenImmunogen: Synthesized peptide derived from part region of human FPR2 protein at amino acid sequence of 130-210
Other Names[Rabbit FPR2; N-formyl peptide receptor 2; FMLP-related receptor I; FMLP-R-I; Formyl peptide receptor-like 1; HM63; Lipoxin A4 receptor; LXA4 receptor; RFP]
Gene, Accession #[FPR2], Gene ID: 2358, NCBI: NP_001453.1, UniProt: P25090
Catalog #MBS9709168
Price$130, $220, $325
Order / More InfoFPR2 Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.